181 related articles for article (PubMed ID: 32386053)
1. Persistence of Clinically Significant Portal Hypertension After Eradication of Hepatitis C Virus in Patients With Advanced Cirrhosis.
Díez C; Berenguer J; Ibañez-Samaniego L; Llop E; Pérez-Latorre L; Catalina MV; Hontañón V; Jiménez-Sousa MA; Aldámiz-Echevarría T; Martínez J; Calleja JL; Albillos A; Bellón JM; Resino S; González-García J; Bañares R
Clin Infect Dis; 2020 Dec; 71(10):2726-2729. PubMed ID: 32386053
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
Lens S; Baiges A; Alvarado-Tapias E; LLop E; Martinez J; Fortea JI; Ibáñez-Samaniego L; Mariño Z; Rodríguez-Tajes S; Gallego A; Bañares R; Puente Á; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; García-Pagán JC; Forns X
J Hepatol; 2020 Dec; 73(6):1415-1424. PubMed ID: 32535060
[TBL] [Abstract][Full Text] [Related]
3. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.
Lens S; Alvarado-Tapias E; Mariño Z; Londoño MC; LLop E; Martinez J; Fortea JI; Ibañez L; Ariza X; Baiges A; Gallego A; Bañares R; Puente A; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; Forns X; García-Pagán JC
Gastroenterology; 2017 Nov; 153(5):1273-1283.e1. PubMed ID: 28734831
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 years follow-up of a prospective longitudinal study.
Knop V; Hoppe D; Vermehren J; Troetschler S; Herrmann E; Vermehren A; Friedrich-Rust M; Sarrazin C; Trebicka J; Zeuzem S; Welker MW
J Viral Hepat; 2021 Nov; 28(11):1604-1613. PubMed ID: 34342081
[TBL] [Abstract][Full Text] [Related]
5. Spleen size change after hepatitis C treatment: a simple parameter to predict clinical outcomes.
Prakash S; Kinder K; Brown KE
J Investig Med; 2023 Aug; 71(6):603-612. PubMed ID: 37144285
[TBL] [Abstract][Full Text] [Related]
6. Blood microbiome is associated with changes in portal hypertension after successful direct-acting antiviral therapy in patients with HCV-related cirrhosis.
Virseda-Berdices A; Brochado-Kith O; Díez C; Hontañon V; Berenguer J; González-García J; Rojo D; Fernández-Rodríguez A; Ibañez-Samaniego L; Llop-Herrera E; Olveira A; Perez-Latorre L; Barbas C; Rava M; Resino S; Jiménez-Sousa MA
J Antimicrob Chemother; 2022 Feb; 77(3):719-726. PubMed ID: 34888660
[TBL] [Abstract][Full Text] [Related]
7. Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy.
Puente Á; Cabezas J; López Arias MJ; Fortea JI; Arias MT; Estébanez Á; Casafont F; Fábrega E; Crespo J
Rev Esp Enferm Dig; 2017 Jan; 109(1):17-25. PubMed ID: 27990835
[TBL] [Abstract][Full Text] [Related]
8. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.
Afdhal N; Everson GT; Calleja JL; McCaughan GW; Bosch J; Brainard DM; McHutchison JG; De-Oertel S; An D; Charlton M; Reddy KR; Asselah T; Gane E; Curry MP; Forns X
J Viral Hepat; 2017 Oct; 24(10):823-831. PubMed ID: 28295923
[TBL] [Abstract][Full Text] [Related]
9. Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy.
Lens S; Rincón D; García-Retortillo M; Albillos A; Calleja JL; Bañares R; Abraldes JG; Bosch J; Sanchez-Tapias JM; Forns X; García-Pagán JC
Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1846-1853.e1. PubMed ID: 25912838
[TBL] [Abstract][Full Text] [Related]
10. Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis.
Kotani K; Enomoto M; Uchida-Kobayashi S; Tamori A; Yukawa-Muto Y; Odagiri N; Motoyama H; Kozuka R; Kawamura E; Hagihara A; Fujii H; Kageyama K; Yamamoto A; Yoshida A; Higashiyama S; Kawabe J; Kawada N
J Gastroenterol; 2023 Apr; 58(4):394-404. PubMed ID: 36729172
[TBL] [Abstract][Full Text] [Related]
11. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals.
Corma-Gómez A; Macías J; Téllez F; Freyre-Carrillo C; Morano L; Rivero-Juárez A; Ríos MJ; Alados JC; Vera-Méndez FJ; Merchante N; Palacios R; Granados R; Merino D; De Los Santos I; Pineda JA
Clin Infect Dis; 2020 Dec; 71(9):2354-2362. PubMed ID: 31754695
[TBL] [Abstract][Full Text] [Related]
12. Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals.
Tajiri K; Okada K; Ito H; Kawai K; Kashii Y; Tokimitsu Y; Muraishi N; Murayama A; Hayashi Y; Minemura M; Takahara T; Shimizu Y; Yasuda I
BMC Gastroenterol; 2023 May; 23(1):182. PubMed ID: 37231349
[TBL] [Abstract][Full Text] [Related]
13. Management of betablocked patients after sustained virological response in hepatitis C cirrhosis.
Abadía M; Montes ML; Ponce D; Froilán C; Romero M; Poza J; Hernández T; Fernández-Martos R; Olveira A;
World J Gastroenterol; 2019 Jun; 25(21):2665-2674. PubMed ID: 31210717
[TBL] [Abstract][Full Text] [Related]
14. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection.
Reiberger T; Rutter K; Ferlitsch A; Payer BA; Hofer H; Beinhardt S; Kundi M; Ferenci P; Gangl A; Trauner M; Peck-Radosavljevic M
Clin Gastroenterol Hepatol; 2011 Jul; 9(7):602-8.e1. PubMed ID: 21397726
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A
J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844
[TBL] [Abstract][Full Text] [Related]
16. Direct-Acting Antivirals Reduce the De Novo Development of Esophageal Varices in Patients with Hepatitis C Virus Related Liver Cirrhosis.
Hsieh YY; Chen WM; Chang KC; Chang TS; Hung CH; Yang YH; Tung SY; Wei KL; Shen CH; Wu CS; Ding YJ; Hu JH; Huang YT; Lin MH; Lu CK; Lin YH; Lin MS
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680293
[TBL] [Abstract][Full Text] [Related]
17. Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy.
Petta S; Rini F; Calvaruso V; Cammà C; Ciminnisi S; Di Marco V; Giannini EG; Grimaudo S; Maria Pipitone R; Craxì A
Liver Int; 2020 Mar; 40(3):530-538. PubMed ID: 31507057
[TBL] [Abstract][Full Text] [Related]
18. Effect of Direct-Acting Antiviral Agents on Gastroesophageal Varices in Patients with Hepatitis C Virus-Related Cirrhosis.
Hisanaga H; Takedatsu H; Emori K; Inoue H; Kunitake Y; Nakane T; Fukunaga S; Ide T; Mitsuyama K; Torimura T
Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013545
[TBL] [Abstract][Full Text] [Related]
19. [The long-term prospective study of patients with liver cirrhosis after elimination of the hepatitis C virus].
Nabatchikova EA; Abdurakhmanov DT; Nikulkina EN; Rozina TP; Tanaschuk EL; Nikiforova NV; Adonyeva VS; Moiseev SV
Ter Arkh; 2020 Apr; 92(2):34-42. PubMed ID: 32598716
[TBL] [Abstract][Full Text] [Related]
20. Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension.
Di Marco V; Calvaruso V; Ferraro D; Bavetta MG; Cabibbo G; Conte E; Cammà C; Grimaudo S; Pipitone RM; Simone F; Peralta S; Arini A; Craxì A
Gastroenterology; 2016 Jul; 151(1):130-139.e2. PubMed ID: 27039970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
